| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| HLA-A*0301 & B2M | Human HLA-A*03:01&B2M Monomer Protein (Peptide free, MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug | |||
| HLA-A*0301 & B2M | Biotinylated Human HLA-A*03:01&B2M Monomer Protein (Peptide free, MALS verified) | Human | HEK293 | MALSSDS-PAGE | $145.00 25ug | |||
| HLA-A*0301 & B2M | PE-Labeled Human HLA-A*03:01&B2M Tetramer Protein (Peptide free) | Human | HEK293 | $410.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Vopratelimab | JTX-2011 | Phase 2 Clinical | Jounce Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Izuralimab | XmAb-23104; XmAb-104 | Phase 2 Clinical | Xencor Inc | Sarcoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms | Details |
| Feladilimab | GSK-609; GSK-3359609 | Phase 2 Clinical | Glaxosmithkline Plc | Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Multiple Myeloma | Details |
| Alomfilimab | KY-1044 | Phase 2 Clinical | Kymab Ltd | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| Acazicolcept | ALPN-101 | Phase 2 Clinical | Graft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation | Details | |
| MEDI-570 | Phase 1 Clinical | Japan Tobacco (Hong Kong) Ltd | Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Mycosis Fungoides | Details | |
| Anti-ICOS (Bristol Myers Squibb) | BMS-986226 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
